Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants

BACKGROUND: Lenvatinib is an oral, multitargeted, tyrosine kinase inhibitor under clinical investigation in solid tumors. In vitro evidence indicates that lenvatinib metabolism may be modulated by ketoconazole, an inhibitor of CYP3A4 and p-glycoprotein. METHODS: In this Phase I, single-center, rando...

Descripción completa

Detalles Bibliográficos
Autores principales: Shumaker, Robert, Aluri, Jagadeesh, Fan, Jean, Martinez, Gresel, Thompson, Gary A, Ren, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467237/
https://www.ncbi.nlm.nih.gov/pubmed/26097795
http://dx.doi.org/10.1002/cpdd.140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467237/
https://www.ncbi.nlm.nih.gov/pubmed/26097795
http://dx.doi.org/10.1002/cpdd.140

Ejemplares similares